*Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, New York;
†Vitreous Retina Macula Consultants of New York, New York;
‡LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York;
§Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, New York, New York;
¶Department of Ophthalmology, New York University School of Medicine, New York, New York; and
**Brighton Eye Associates, Brooklyn, New York.
Reprint requests: Richard B. Rosen, Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, NY 10003; e-mail: [email protected]
Supported by The Macula Foundation, Inc, New York, NY.
K. B. Freund is a consultant for Optovue, Optos, Heidelberg Engineering, Genentech, and Spark Therapeutics. He receives research support from Genentech/Roche. R. D.-Marco receives research support from Novartis, Alcon, Thea and Genentech/Roche. R. B. Rosen is a consultant for Optovue, NanoRetina, Regeneron, Ocata Therapeutics, Guardion Health, Glaucohealth, Allergan, Boehringer-Ingelheim, CellView and receives grant support from Genentech/Roche, Zeavision, and NanoRetina. None of these are relevant to this report. R. C. Gentile has no relevant commercial relationships to disclose. He is a PI or Sub-PI for Institutional Research funded by: Genentech, Inc; Regeneron Pharmaceuticals, Inc; Alcon; Allergan; Jaeb Center for Health Research. The remaining authors have no conflicting interests to disclose.The imaging lab was supported by the following NIH grants: NIH- 1R01EY027301 and NEI- U01 EY025477-01.
